NEWHealth

Lilly (LLY) obesity pill reduces cardiovascular risks in trial

Published on 4/16/2026

#LLY#obesity#cardiovascular#type2diabetes
Lilly (LLY) obesity pill reduces cardiovascular risks in trial

AI Summary

Eli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.

Source: Read original article (opens in new tab)

Related News

FDA Weighs Lifting Peptide Restrictions Impacting HIMS
Health

FDA Weighs Lifting Peptide Restrictions Impacting HIMS

Apr 16

Asgard Therapeutics (ASGD) Appoints Wolfram Brugger as CMO
Health

Asgard Therapeutics (ASGD) Appoints Wolfram Brugger as CMO

Apr 14

Osteoarthritis Drug Shows Potential in Joint Regrowth Studies
Health

Osteoarthritis Drug Shows Potential in Joint Regrowth Studies

Apr 11

Eli Lilly (LLY) market share drops to 56% in India as generics flood
Pharma

Eli Lilly (LLY) market share drops to 56% in India as generics flood

Apr 10